ILARIA GRAZIA ZIZZARI

GENERAL INFORMATION
Full Name: Ilaria Grazia Zizzari
Citizenship: Italian

E-mail: ilaria.zizzari@uniroma1.it

PRESENT POSITION

02.05.2025 –to date: Associate Professor SSD MEDS02/A (ex-MED/04) Department of Experimental
Medicine, Laboratory of Tumor Immunology and Cell Therapies, Sapienza University
of Rome

EDUCATION

October 2023-June 2025: VI edition of QUID: the Sapienza Program for the Enhancement of the Teaching
Tutorial: Piattaforme informatiche per una didattica efficace" 17.11.2023
Tutorial: Buone prassi e linee guida per gli studenti con disabilità e DSA” 16.02.2024
Tutorial: Come scegliere e progettare una prova d'esame. 13.12.2024
Tutorial: Pratiche didattiche per l’apprendimento attivo. 10.01.2025

2016: Clinical Pathology Specialization
Sapienza University Rome, Policlinico Umberto I (01.10.2011-06.09.2016)

March-June 2013: Course of "Writing Scientific Articles", Cattolica University, Rome

November 2011: Course in Clinical Immunology, EFIS-EJI (The European Network of Immunology
Institutes), Paris

2011: PhD in Immunological Science, XXIII cycle
Department of Experimental Medicine, Laboratory of Tumor Immunology
and Cell Therapies, Sapienza University of Rome (01.11.2007-11.03.2011)

October –December 2010: cGMP course for Cell Therapy, Sapienza University, Rome

November 2009: License to practice as Biologist

April 2009: Flow Cytometry course at Becton Dickinson Spa, Milan

2007: Graduated with honors (110/110 cum laude) in Medical and Molecular
Biotechnology, Sapienza University of Rome

WORKING EXPERIENCE

2022-2025: RTD-B MEDS02/A (ex MED/04) Department of Experimental Medicine, Sapienza
University of Rome
31 Aug 2022-
31 Jan 2023: Maternity leave

2020–2022: RTD-A MED/05 Department of Experimental Medicine, Sapienza University of Rome

December 2018-
June 2019: Maternity leave

2011- 2015 Dendritic Cell Production Operator, UP Cell Therapies (EP003), Policlinico
Umberto I-Sapienza University of Rome

2011- 2020: Research Post-Doc Fellowship SSD MED/04 cat.B, type II
Department of Experimental Medicine, Sapienza University of Rome:
 2011-2014 Project “Application of stem cells in rigenerative medicine” co-founded by Regione Lazio (ai sensi dell’art.51 della Legge 449/97)
 2013 Project “La Lectina MGL come modulatore dell’immunosoppressione nei vaccini antitumore” (ai sensi dell’art. 22 della Legge 240/2010) (waiver to resume third year of renewal of the co-financed allowance by the Regione Lazio pursuant to Article 51 of Law 449/97)
 2014-2015 Project: “Ruolo della lectina MGL nell’immunità innata” (ai sensi dell’art. 22 della Legge 240/2010)
 2015-2016 Project: “The role of MGL in DC-NK crosstalk” (ai sensi dell’art. 22 della Legge 240/2010)
 2016-2020* Project: “Glycoantigens in ovarian cancer: dissecting novel patterns of immune recognition in cancer patients” (ai sensi dell’art. 22 della Legge 240/2010)
*(maternity leave 24.12.18 - 30.06.19)

ACCADEMIC APPOINTEMENTS

2023-to date: Member of the Quality Assurance Management Commission (CGAQ) (code: 30896) Course
in Medicine and Surgery, Section “D”- Sapienza University of Rome

2023-to date: Member of the Quality Assurance Management Commission (CGAQ) PhD course in Network
Oncology and Precision Medicine (30887)-Sapienza University of Rome

2023-to date: Member of the Scientific Board of the II level Master in Immuno-Oncology and Cell Therapy
(code: 29056), Sapienza University of Rome

2023-to date: Member of the Strategic Plan Working Group, Department of Experimental Medicine,
Sapienza University of Rome

2022–to date: Member of the Scientific Board of the II level Master in Medicina Trasfusionale:
Immunoematologia Eritropiastrinica (31469) - Sapienza University of Rome

2022-to date: Board Member of 2° Residency School in Clinical Pathology and Clinical Biochemistry
Sant’Andrea Hospital-Sapienza University of Rome

2020-to date: Member of Scientific experts established at the MIUR (REPRISE) for the section “Basic
Research”

2020 –to date: Board Member PhD Course in "Network Oncology and Precision Medicine"(code: 30887),
Sapienza University of Rome

2021-2023: Member of the Scientific Board of the II level Master in “Immuno-Oncology” (cod.29056),
Sapienza University of Rome

2016-2021: Member of the coordination group II level Master in “Immuno-Oncology” (cod.29056),
Sapienza University of Rome

2018-2020: Elected Representative of Research fellows of the Department of Experimental Medicine,
Sapienza University of Rome

2017-2020: Member of the working group for "Immunological Monitoring in Clinical Trials of
“Experimental Immunotherapy in Oncology" within the project "Rete del Lazio per
la Medicina Traslazionale e Sviluppo delle Bioterapie dei tumori” coordinated by Istituto
Superiore di Sanità

TEACHING AND TUTORING EXPERIENCE

Degree Course

2016-2018: Subject expert, "Clinical Nursing in Specialized Area" Course, "Oncology" Module, second year,
2019-2020 second semester Nursing Degree Course V, Viterbo campus, University Sapienza of Rome

2017-2018: Teaching of Clinical Biochemistry and Molecular Biology BIO/12, Course of Physiopathological
bases of diseases, Health Assistants Course, Sapienza University of Rome

2020 – to date: Teaching of General Pathology and Pathophysiology MED/04 (1025586), Course of Medicine and
Surgery D, Sapienza University of Rome- 2 CFU (28h)

2020 – to date: Teaching of Physiology BIO/09 (1034952), Course of Anatomo-physiological basis of the human
body, Nursing Course J - ASL Roma 1, Sapienza University of Rome -1 CFU (12h. 2CFU-24h since
a.a 2024/2025)

2020 – to date: Teaching of Clinical Pathology MED/05 (1047789), Course of Physiopathological bases of
diseases, Occupational Therapy Course A, Sapienza University of Rome -1 CFU (12 hours)

2020 – to date: Teaching of Technical Sciences of Laboratory Medicine MED/46 (10589388), Course of
Physio-pathological bases of diseases, Nursing Course G - ASL Roma 5-Colleferro, Sapienza
University of Rome -1 CFU (12 hours)

2023 - to date: Seminar activity Nursing Degree Course J (MEDS02/A) (AAF1405)- ASL Roma 1 L/SNT1
Sapienza University of Rome -1 CFU (6 hours)

2023-to date: Tutor for Elective Teaching Activities (ADE) (MEDS02/A) (AAF1433) for students of the Degree
Course in Health Care - Rome Azienda Policlinico Umberto I L/SNT4- Sapienza University of
Rome –1 CFU (12 hours)

2024-to date: Teaching of Physiopathological Bases of Diseases - General Pathology Module (MEDS02/A)
(10589388)- Degree Course in Nursing V - ASL Viterbo - Sapienza University of Rome-1 CFU
(12 hours)

Master, PhD and Specialization School

2023-to date: Professor at II level Master in “Immuno-Oncology and Cell-Therapies” (Cod.32680)-
Sapienza University of Rome

2022-to date: Professor at II level “Medicina Trasfusionale: Immunoematologia Eritropiastrinica"
(Cod.31469) Sapienza University of Rome

2016-2023: Professor at II level Master in “Immuno-Oncology” (cod.29056), Sapienza University of Rome

2021: Seminar at 2° Residency School in Clinical Pathology and Clinical Biochemistry
Sant’Andrea Hospital-Sapienza University of Rome

Tutoring activity

2020 – to date: Tutor for Elective Teaching Activities (ADE), Teaching of General Pathology and
Pathophysiology MED/04, Course of Medicine and Surgery D, Sapienza University of Rome

2020 - to date: Tutoring and orientation activities for students of various Sapienza Degree courses (Biology,
Biothecnology, Medicine, Statistical Science) and the PhD in Network Oncology and Precision Medicine

2024: Tutor Project for Starting Research 2024 PhD student (Angela Asquino) Circulating immune
checkpoint inhibitors in head and neck cancer patients treated with immunotherapy:
correlation between immune profile and clinical parameters (Protocol number:
AR12419074967E5A)

2023: Tutor Project for Starting Research 2023 PhD student (Fabio Scirocchi) Investigating
immunological mechanisms to enhance the anti-tumor immune response in HR+/HER2-
metastatic breast cancer patients undergoing CDK4/6 inhibitor treatment by studying
costimulation and exhaustion in CD8+ T cells. (Protocol number: AR223188B4143407)

2022: Tutor Project for Starting Research 2022 PhD student (Fabio Scirocchi) CDK4/6 inhibitors as
novel immunomodulatory drugs: the impact on T reg differentiation in breast cancer (Protocol
number: AR122181681F1A82)

PATENT, OUTREACH, PUBLIC ENGAGEMENT AND ORIENTATION ACTIVITIES

2023-to date: Orientation and Transversal Skills Courses (POCT), Sapienza University of Rome
‘How to interrogate the immune system to obtain information on our state of health’
(nr. 112192 for a.a 2023/24; nr. 138649 for a.a 2024/25, Istituto tecnico “Carlo and Nello
Rosselli” Aprilia Rome)

16.05.2024: Co-inventor of the Patent “Method for determining the prognostic score in patients with metastatic
renal carcinoma” (N.102022000011795; PCT/IB2023/055561, Property 100% Sapienza University
of Rome). Request for foreign extension filed on 7/12/2023 under no. WO2023/233310A1).
(Patent application filed in EUROPE on 11.12.24 no. 23735080.6; INDIA on 24.12.24 no.
202417102640; USA application no. 18/864,760 on 11.11.2024; Japan no. 2024-571136 on
02/12/2024)

2024: Orientation courses delivered to High School students, as part of PNRR- Next Generation EU-
Sapienza University of Rome

FUNDING INFORMATION

Grant as Principal Investigator (PI)

2023-2025: PI Project PRIN 2022 “Dissecting naïve PD-1+ T-cells phenotype to generate new biological insights of immunotherapy response in advanced NSCLC (cod.2022K5RYF5, Euro 200.981)
2023-2025: PI Project PRIN PNRR 2022 “Cellular, molecular, radiological and clinical determinants of skeletal fragility in patients with acromegaly: the role of inflammation and GH-lowering medical therapies. A cross-sectional and prospective study” (cod. P2022S9M93, Euro 238.191, since September 2024)

2023-2026: PI Project “Progetto Grande di Ateneo 2023”: Dissecting molecular and functional pathways of CD137+ effector and regulatory T cell subsets to improve immunotherapy efficacy in mRCC patients (RG123188B4C6C54B, Euro 26.000)
2023-2025: PI Project "Proof of Concept (PoC) PNRR 2023 - NextGenerationEU" Ministero delle Imprese e del Made in Italy and Sapienza University (CUP C88H23000760001) “Dall'algorItmo progNostico al proTotipo clinical Use: lo svIluppo applicaTivo dell'ImmunO-IMDC–(INTUITO) (codice: C88H23000760001, Euro 66.200)

2022-2024: PI Project “Ricerca di Ateneo 2021 (Medio). Title of the project: “Network Medicine In Immuno-Oncology: Integrating Clinical And Laboratory Data To Generate Precision Roadmaps For Cancer (codice: RM12117A85361029, Euro 10.000)
2022: co-PI and PROJECT MANAGER Restricted Research Evaluation Grant Agreement between Beckman Coulter srl and Department of Experimental Medicine, Sapienza University. Title of the project: “Immune-profile of cancer patients: integrate clinical and immunological data for a precision medicine in the era of immunotherapy” (Euro 10.000)
2021-2022: PI Project “Ricerca di Ateneo 2020 (Piccoli). Title of the project: “Impact of circulating immune molecules on clinical outcome of uveal melanoma patients” (N°: RP120172A7DF1B76, Euro 3000).
2017-2018: PI Project “Avvio alla ricerca, tipologia B, bando Ricerca Scientifica Sapienza 2017. Title of the project: “Prognostic and predictive role of microbioma in NSCLC patients treated with anti-PD1 therapy” (N°: AR21715C5E4E4300, Euro 2000).
2016-2017: PI Project “Avvio alla ricerca, tipologia B, bando Ricerca Scientifica Sapienza 2016”. Title of the project:“Immune checkpoint inhibitors and immune fitness: new predictive biomarkers for optimal clinical efficacy” (N°:AR216154CDB95AC5, Euro 2000).
2014-2015: PI Project “Avvio alla ricerca, tipologia B, bando Ricerca Scientifica Sapienza 2014. Title of the
project: “The role of MGL in DC-NK crosstalk” (N°:C26N14AHKZ, Euro 2200).
2013-2014: PI Project “Avvio alla ricerca, tipologia B, Ricerca Scientifica Sapienza Anno 2013. Title of the project:“Generation and characterization of novel recombinant immunogens to target DCs for cancer vaccines" (n°:C26N13XPZA, Euro 2000).
Grant as Investigator

2023-to date: Investigator Project PNRR 2023-Partenariato Esteso 10 Spoke 6 Tackle malnutrition. Focus on sarcopenic obesity (PI Giannetta E, Euro 841.000).

2022-2024: Investigator Project “Ricerca di Ateneo- Progetti Medi 2022 (PI Rughetti A, n.: RM1221816BCE0EAA, Euro 10.000)

2022-2024: Investigator Progetto Grandi Attrezzature Scientifiche - Grandi Attrezzature 2022 (PI Ferretti E, Numero protocollo: GA122181B3E04379, Euro 425.000)

2018-2020: Investigator Project “Ricerca di Ateneo- Progetti Medi 2018: “Glioblastoma Multiforme
(GBM): investigating the mechanisms by which the tumor glyco-code modulates anti-tumor immunity” (PI Rughetti A, n.: RM1181643132016E, 10.000,00 euro)

2015-2018: Investigator: "AIRC Investigator Grant 2015". Project: "Glycoantigens in ovarian cancer: dissecting novel patterns of immune recognition in cancer patients" (AIRC: IG 2015 Id.17432, PI: Prof.ssa Marianna Nuti, Euro 320.000).
2013-2016: Investigator PRIN 2010-2011. Project: “Le scienze“omiche” come strumento per la ricerca traslazionale in neuroncologia” (n.°: 2010ZESJWN_003: Scientific Coordinator Prof. Tomasello Francesco)
2011-2013: Investigator PRIN 2009. Project: "Meccanismi di immunosoppressione/tolleranza nell' interazione tumore e sistema immunitario: identificazione di nuove strategie per ristabilire l'immunosorveglianza" (n°:2009XMZPKW_001; Scientific Coordinator: Prof.ssa Nuti Marianna)
2009-2012: Investigator "AIRC Investigator Grant 2009" (Associazione Italiana per la Ricerca Cancro). Project: "MGL receptor on dendritic cells: novel mechanism of DC targeting for cancer vaccination". (AIRC: IG 2009 Id.9249, PI: Prof.ssa Marianna Nuti, Euro 250.000).

ON GOING MAIN SCIENTIFIC COLLABORATIONS supported by publications and grants

• Prof. Santini D, Prof. Botticelli A, Dott.Gelibter A, Medical Oncology Unit, Department of Clinical and Molecular Medicine and Department f Radiological, Oncological and Pathological Science, Sapienza University of Rome

• Prof. Conti, Dott. Ceccarelli F., Lupus Clinic, Rheumatology, Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome

• Prof. Farina L, Prof. Petti M, Department of Computer, Control, and Management Engineering at Sapienza University of Rome

• Prof.ssa Antiochia R. Department of Chemistry and Drug Technology at Sapienza University of Rome

• Prof. Calabrò F., Medical Oncology Istituto Nazionale Tumori Regina Elena

• Dott. Rossi E., Medical Oncology Unit, Fondazione-Policlinico Agostino Gemelli-Cattolica University, Rome

• Prof.ssa Guerini E, Department of Oncology and Hemato-Oncology, University of Milan -IEO Milan

• Prof. Marchetti P., IDI e Fondazione per la Medicina Personalizzata

• Prof. Alvaro D., Prof. Cardinale V. Department of Translational and Precision Medicine, Sapienza University of Rome.

EDITORIAL EXPERIENCE

2022-to date: Associated Editor for Frontiers in Oncology, Frontiers

2020-2023: Academic Editor for Oncology section, BioMed Research International, Wiley

2020-2021: Guest Editor for the Special Issue: "Immunocyto/Histochemistry in the Era of
Immunotherapy " Journal of Personalized Medicine", MDPI

2017-2018: Guest Editor for the Special Issue “Immunobiology of Solid Cancers: Cellular and Molecular
Pathways as Potential Diagnostic and Therapeutic Targets” BioMed Research International,
Hindawi

AWARDS, HONORS and SOCIETY MEMBERSHIPS

2025 Abstract selected for oral presentation: Cirillo A., Asquino A….Zizzari IG.
Novel circulating biomarkers in HNSCC patients receiving anti-PD1 therapy: the predictive and prognostic role of immunosuppressive CD137⁺Treg cells and LOX-1+ PMN-MDSCs, ECHNO2025, European Congress on Head and Neck Oncology to be held March 26-29th 2025 in Amsterdam.

2011: Selected candidate for the Bursary Programme of the EFIS-EJI Course in “Clinical Immunology”,
Paris 28-30 November 2011

2010: Abstract selected for oral presentation: Zizzari I, Napoletano C, Rughetti A, Nuti M
Mgl engagement modulates Dc phenotype and induces Erk1/2 and Nf-ΚB signaling pathways
5th ENII EFIS/EJI Immunology Summer School 2010, 9-16 May, Capo Caccia, Sardinia

2010: Fellowship winner ENII/EFIS (The European Network of Immunology Institutes) for the 5th
Immunology Summer School, Capo Caccia 9-16 May 2010

2009: Abstract selected for oral presentation: Zizzari I, Veglia F, Rahimi H, Napoletano C, Bellati F,
Benedetti Panici P, Frati L, Rughetti A. HER2-based recombinant immunogen for dendritic cells
targeting through FcγR 2nd International Congress of Immunology ECI, Berlin 13-16 September
2009

Member of SIICA Scientific society (Società Italiana di Immunologia, Immunologia Clinica ed Allergologia) since 2008

Member of SIPMET Scientific society (Società Italiana di Patologia e Medicina Traslazionale) since 2011

Member of MITO Scientific society (Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies) 2015

Member of GIC (Italian Society of Cytometry) since 2023

SCIENTIFIC PRODUCTION
Research identifiers:
ORCID ID: 0000-0001-8263-7248, SCOPUS AUTHOR ID: 46661944300
Author position’s Summary: First author: 13/57; Last author: 3/57; corresponding: 5/57

1. Sibilio P, Zizzari IG*, Gelibter A, Siringo M, Tuosto L, Pace A, Asquino A, Valentino F, Sabatini
A, Petti M, Bellati F, Santini D, Nuti M, Farina L, Rughetti A, Napoletano C. Immunological Network
Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-
PD1 Therapy: A Pilot Study. Cancers (Basel). 2025;17(6):922. doi: 10.3390/cancers17060922.

2. Zizzari IG, Gigli V, Gentili T, Tortolini C, Latini A, Rughetti A, di Gregorio MC, Isidori A, Nuti M,
Antiochia R. An ecofriendly iron MOF-based immunosensor for sensitive detection of vascular
endothelial growth factor in the serum of cancer patients. Nanoscale. 2025;17(14):8790-8802.
doi: 10.1039/d5nr00471c.

3. Gelibter A, Tuosto L, Asquino A, Siringo M, Sabatini A, Zizzari IG, Pace A, Scirocchi F, Valentino F, Bianchini S, Caponnetto S, Paoli D, Bellati F, Santini D, Nuti M, Rughetti A, Napoletano C. Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients.
Front Immunol. 2024 doi: 10.3389/fimmu.2024.1483182 (IF 2023 5.700) (WOS 2023 Q1) (Cit.0)

4. Gnagni L, Ruscito I, Zizzari IG, Nuti M, Napoletano C, Rughetti A. Precision Oncology Targeting FGFRs: A Systematic Review on Preclinical Activity and Clinical Outcomes of Pemigatinib.
Crit Rev Oncol Hematol. 2024 doi.org/10.1016/j.critrevonc.2024.104464 (IF 2023 5.500) (WOS 2023 Q1) (Cit.0)

5. Gelibter A, Asquino A, Strigari L, Zizzari IG, Tuosto L, Scirocchi F, Pace A, Siringo M, Tramontano E, Bianchini S, Bellati F, Botticelli A, Paoli D, Santini D, Nuti M, Rughetti A, Napoletano C. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.
J Transl Med. 2024; doi: 10.1186/s12967-024-05142-6. (IF 2023 6.100) (WOS 2023 Q1) (Cit.2)

6. Pace A, Scirocchi F, Napoletano C, Zizzari IG, Po A, Megiorni F, Asquino A, Pontecorvi P, Rahimi H, Marchese C, Ferretti E, Nuti M, Rughetti A. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
J Transl Med. 2023; doi: 10.1186/s12967-023-04450-7. (IF 2023 6.100) (WOS 2023 Q1) (Cit.4)

7. Mezi S, Pomati G, Fiscon G, Amirhassankhani S, Zizzari IG, Napoletano C, Rughetti A, Rossi E, Schinzari G, Tortora G, Lanzetta G, D'Amati G, Nuti M, Santini D, Botticelli A. A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors.
Front Immunol. 2023; doi: 10.3389/fimmu.2023.1199089. (IF 2023 5.700) (WOS 2023 Q1) (Cit.0)

8. Botticelli A, Cirillo A, Pomati G, Cortesi E, Rossi E, Schinzari G, Tortora G, Tomao S, Fiscon G, Farina L, Scagnoli S, Pisegna S, Ciurluini F, Chiavassa A, Amirhassankhani S, Ceccarelli F, Conti F, Di Filippo A, Zizzari IG, Napoletano C, Rughetti A, Nuti M, Mezi S, Marchetti P. Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Cancer Immunol Immunother. 2023; doi: 10.1007/s00262-023-03384-9. (IF 2023 4.600) (WOS 2023 Q1) (Cit.3)

9. Ceccarelli F, Natalucci F, Di Filippo A, Olivieri G, Napoletano C, Rughetti A, Nuti M, Zizzari IG*, Conti F* Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity.
J Immunol Res. 2023; doi: 10.1155/2023/2344239 (IF 2023 3.500) (WOS 2023 Q2) (Cit.4)
*Equal contribution
Corresponding

10. Cirillo A*, Zizzari IG*, Botticelli A, Strigari L, Rahimi H, Scagnoli S, Scirocchi F, Pernazza A, Pace A, Cerbelli B, d'Amati G, Marchetti P, Nuti M, Rughetti A, Napoletano C. Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients.
Int J Mol Sci. 2023; doi: 10.3390/ijms24087114. (IF 2023 4.900) (WOS 2023 Q1) (Cit.4)
*Equal contribution

11. Cardinale V, Carpino G, Overi D, Safarikia S, Zhang W, Kanke M, Franchitto A, Costantini D, Riccioni O, Nevi L, Chiappetta M, Onori P, Franchitto M, Bini S, Hung YH, Lai Q, Zizzari I, Nuti M, Nicoletti C, Checquolo S, Di Magno L, Giuli MV, Rossi M, Sethupathy P, Reid LM, Alvaro D, Gaudio. Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential.
E.J Hepatol. 2023 doi: 10.1016/j.jhep.2022.08.037 (IF 2023 26.800) (WOS 2023 Q1) (Cit.9)

12. Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, Botticelli A, Rughetti A, Nuti M, Zizzari IG*. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Int J Mol Sci. 2022 doi: 10.3390/ijms232214496 (IF 2022 5.600) (WOS 2022 Q1) (IF 2023 4.900) (WOS 2023 Q1) (Cit.25)
*Corresponding

13. Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Front Immunol. 2022. doi: 10.3389/fimmu.2022.974087 (IF 2022 7.300) (WOS 2022 Q1) (IF 2023 5.700) (WOS 2023 Q1) (Cit.14)

14. Mezi S, Pomati G, Zizzari IG, Di Filippo A, Cerbelli B, Cirillo A, Fiscon G, Amirhassankhani S, Valentini V, De Vincentiis M, Corsi A, Di Gioia C, Tombolini V, Della Rocca C, Polimeni A, Nuti M, Marchetti P, Botticelli.Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile.
Biomedicines. 2022 doi: 10.3390/biomedicines10112732 (IF 2022 4.700) (WOS 2022 Q2) (IF 2023 3.900) (WOS 2023 Q2) (Cit.3)

15. Pace A, Scirocchi F, Napoletano C, Zizzari IG, D'Angelo L, Santoro A, Nuti M, Rahimi H, Rughetti A. Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.
Int J Mol Sci. 2022, doi: 10.3390/ijms23116312 (IF 2022 5.600) (WOS 2022 Q1) (IF 2023 4.900) (WOS 2023 Q1) (Cit.7)

16. Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, Strigari L, Tomao S, Cortesi E, Rughetti A, Marchetti P, Nuti M. Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.
EBioMedicine. 2022; doi: 10.1016/j.ebiom.2022.104010 (IF 2022 11.100) (WOS 2022 Q1) (IF 2023 9.700) (WOS 2023 Q1) (Cit.34)

17. Zizzari IG, Di Filippo A, Botticelli A, Strigari L, Pernazza A, Rullo E, Pignataro MG, Ugolini A, Scirocchi F, Di Pietro FR, Rossi E, Gelibter A, Schinzari G, D’Amati G, Rughetti A, Marchetti P, Nuti M, Napoletano C. Circulating CD137+ T cells correlate with improved response to anti-PD1 Immunotherapy in cancer patients.
Clinical Cancer Research 2022. doi: 10.1158/1078-0432.CCR-21-2918. (IF 2022 11.500) (WOS 2022 Q1) (IF 2023 10.00) (WOS 2023 Q1) (Cit.19)

18. Ernesto Rossi*1 & Ilaria Grazia Zizzari*2, Alessandra Di Filippo2, Anna Acampora3, Monica Maria Pagliara4, Maria Grazia Sammarco4, Maurizio Simmaco5, Luana Lionetto5, Andrea Botticelli6, Emilio Bria1,7, Paolo Marchetti6, Maria Antonietta Blasi4, Giampaolo Tortora1,7, Giovanni Schinzari, Marianna Nuti. Circulating Immune Profile Can Predict Survival Of Metastatic Uveal Melanoma Patients: Results Of An Exploratory Study.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2021 doi: 10.1080/21645515.2022.2034377 (IF 2021 4.526) (WOS 2021 Q3) (IF 2023 4.100) (WOS 2023 Q2) (Cit.9)
*Equal contribution/corresponding

19. Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari IG, Nuti M, Rughetti A. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.
FRONTIERS IN ONCOLOGY 2021. Doi: 10.3389/fonc.2021.755433 (IF 2021 5.738) (WOS 2021 Q2) (IF 2023 3.500) (WOS 2023 Q2) (Cit.22)

20. Botticelli A, Cirillo A, Strigari L, Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Della Rocca C, D'Amati G, Polimeni A, Nuti M, Merlano MC, Mezi S, Marchetti P. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Frontiers In Immunology 2021. doi: 10.3389/fimmu.2021.705096. (IF 2021 8.787) (WOS 2021 Q1) (IF 2023 5.700) (WOS 2023 Q1) (Cit.67)

21. Botticelli A*& ZizzariIG*, Scagnoli S, Pomati G, Strigari L, Cirillo A, Cerbelli B, Di Filippo A,
Napoletano, Scirocchi F, Rughetti A, Nuti M, Mezi S, Marchetti P. The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. JOURNAL OF PERSONALIZED MEDICINE 2021. doi: 10.3390/jpm11070651. (IF 2021 3.508) (WOS 2021 Q2) (IF 2023 3.00) (WOS 2023 Q1) (Cit.38)
*Equal contribution

22. Nevi L, Di Matteo S, Carpino G, Zizzari IG, Safarikia S, Ambrosino V, Costantini D, Overi D, Giancotti A, Monti M, Bosco D, De Peppo V, Oddi A, De Rose AM, Melandro F, Bragazzi MC, Faccioli J, Massironi S, Grazi G, Benedetti Panici P, Berloco PB, Giuliante F, Cardinale V, Invernizzi P, Caretti G, Gaudio E, Alvaro D. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
HEPATOLOGY 2021. doi: 10.1002/hep.31571. (IF 2021 17.298) (WOS 2021 Q1) (IF 2023 13.00) (WOS 2023 Q1) (Cit.37)

23. Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F, Giusti R, Tomassini A, Giampaoli O, Miccheli A, Zizzari IG, Nuti M, Putignani L, Marchetti P. Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. JOURNAL OF TRANSLATIONAL MEDICINE 2020. doi: 10.1186/s12967-020-02231-0. (IF 2020 5.531) (WOS 2020 Q2) (IF 2023 6.100) (WOS 2023 Q1) (Cit.144)

24. Macchia I, La Sorsa V, Ruspantini I, Sanchez M, Tirelli V, Carollo M, Fedele G, Leone P, Schiavoni G, Buccione C, Rizza P, Nisticò P, Palermo B, Morrone S, Stabile H, Rughetti A, Nuti M, Zizzari IG, Fionda C, Maggio R, Capuano C, Quintarelli C, Sinibaldi M, Agrati C, Casetti R, Rozo Gonzalez A, Iacobone F, Gismondi A, Belardelli F, Biffoni M, Urbani F. Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring.
JOURNAL OF IMMUNOLOGY RESEARCH 2020. doi: 10.1155/2020/1938704. (IF 2020 4.818) (WOS 2020 Q2) (IF 2023 3.500) (WOS 2023 Q2) (Cit.10)

25. Botticelli A, Mezi S, Pomati G, Cerbelli B, Cerbelli E, Roberto M, Giusti R, Cortellini A, Lionetto L, Scagnoli S, Zizzari IG, Nuti M, Simmaco M, Marchetti P. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.
FRONTIERS IN IMMUNOLOGY 2020. doi: 10.3389/fimmu.2020.01243. (IF 2020 7.561) (WOS 2020 Q1) (IF 2023 5.700) (WOS 2023 Q1) (Cit.31)

26. Zizzari IG, Filippo AD, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, Scagnoli S, Vernocchi P, Del Chierico F, Putignani L, Rughetti A, Marchetti P, Nuti M, Botticelli A, Napoletano C. Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients.
JOURNAL OF PERSONALIZED MEDICINE 2020. doi: 10.3390/jpm10040208. (IF 2020 4.945) (WOS 2020 Q1) (IF 2023 3.00) (WOS 2023 Q1) (Cit.30)

27. Rahimi Koshkaki H, Minasi S, Ugolini A, Trevisi G, Napoletano C, Zizzari IG, Gessi M, Giangaspero F, Mangiola A, Nuti M, Buttarelli FR, Rughetti A. Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma.
JOURNAL OF PERSONALIZED MEDICINE 2020. doi: 10.3390/jpm10030112. (IF 2020 4.945) (WOS 2020 Q1) (IF 2023 3.00) (WOS 2023 Q1) (Cit.24)

28. Zizzari IG, Napoletano C, Di Filippo A, Botticelli A, Gelibter A, Calabrò F, Rossi E, Schinzari G, Urbano F, Pomati G, Scagnoli S, Rughetti A, Caponnetto S, Marchetti P, Nuti M. Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.
CANCERS 2020. doi:10.3390/cancers12092620. (IF 2020 6.639) (WOS 2020 Q1) (IF 2023 4.500) (WOS 2023 Q1) (Cit.24)

29. Ugolini A, Zizzari IG, Ceccarelli F, Botticelli A, Colasanti T, Strigari L, Rughetti A, Rahimi H, Conti F, Valesini G, Marchetti P, Nuti M. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells.
EBIOMEDICINE 2020. doi: 10.1016/j.ebiom.2020.103098. (IF 2020 8.143) (WOS 2020 Q1) (IF 2023 9.700) (WOS 2023 Q1) (Cit.14)
press release:
https://www.uniroma1.it/en/notizia/immunotherapy-lung-cancer-towards-per...
https://www.dottnet.it/articolo/32449/trovato-il-fattore-nemico-dell-imm...

30. Napoletano C, Steentoff C, Battisti F, Ye Z, Rahimi H, Zizzari IG, Dionisi M, Cerbelli B, Tomao F, French D, d'Amati G, Panici PB, Vakhrushev S, Clausen H, Nuti M, Rughetti A. Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL).
CANCERS 2020. doi: 10.3390/cancers12102841. (IF 2020 6.639) (WOS 2020 Q1) (IF 2023 4.500) (WOS 2023 Q1) (Cit.13)

31. Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, Bria E, Blasi MA, Nuti M, Tortora G. Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
CANCERS 2019. doi: 10.3390/cancers11081055. (IF 2019 6.126) (WOS 2019 Q1) (IF 2023 4.500) (WOS 2023 Q1) (Cit.40)

32. Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, Giusti R, Mazzotta M, Mazzuca F, Roberto M, Vici P, Pizzuti L, Nuti M, Marchetti P. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
JOURNAL OF TRANSLATIONAL MEDICINE 2019. doi: 10.1186/s12967-019-1847-x. (IF 2019 4.124) (WOS 2019 Q2) (IF 2023 6.100) (WOS 2023 Q1) (Cit.49)

33. Napoletano C, Ruscito I, Bellati F, Zizzari IG, Rahimi H, Gasparri ML, Antonilli M, Panici PB, Rughetti A, Nuti M. Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.
JOURNAL OF CLINICAL MEDICINE 2019. doi: 10.3390/jcm8030380. (IF 2019 3.030) (WOS 2019 Q1) (IF 2023 3.00) (WOS 2023 Q1) (Cit.28)

34. Dionisi M, De Archangelis C, Battisti F, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Albano C, Di Filippo A, Torrisi MR, Benedetti Panici P, Napoletano C, Nuti M, Rughetti A. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells. FRONTIERS IN IMMUNOLOGY 2018. doi: 10.3389/fimmu.2018.02481. (IF 2018 4.716) (WOS 2018 Q2) (IF 2023 5.700) (WOS 2023 Q1) (Cit.27)

35. Zizzari IG*, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
CANCER IMMUNOLOGY RESEARCH 2018. doi: 10.1158/2326-6066.CIR-17-0594. (IF 2018 8.619) (WOS 2018 Q1) (IF 2023 8.100) (WOS 2023 Q1) (Cit.49)
*Correspondig

36. Botticelli A, Cerbelli B, Lionetto L, Zizzari IG, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? JOURNAL OF TRANSLATIONAL MEDICINE 2018. doi: 10.1186/s12967-018-1595-3. (IF 2018 4.098) (WOS 2018 Q2) (IF 2023: 6.100) (WOS 2023: Q1) (Cit.98)

37. Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P. The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one.
CANCER TREATMENT REVIEWS 2018. doi: 10.1016/j.ctrv.2018.07.016. (IF 2018 8.332) (WOS 2018 Q1) (IF 2023 9.600) (WOS 2023 Q1) (Cit.23)

38. Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1(ALDH1) in ovarian cancer: A meta-analysis. Gynecologic Oncology 2018. doi: 10.1016/j.ygyno.2018.05.006. (IF 2018 4.393) (WOS 2018 Q2) (IF 2023 4.500) (WOS 2023 Q1) (Cit.23)

39. Napoletano C, Mattiucci S, Colantoni A, Battisti F, Zizzari IG, Rahimi H, Nuti M, Rughetti A. Anisakis pegreffii impacts differentiation and function of human dendritic cells. Parasite Immunology 2018. doi: 10.1111/pim.12527. (IF 2018 2.755) (WOS 2018 Q2) (IF 2023 1.400) (WOS 2023 Q3) (Cit.23)

40. D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors.
CELL DEATH AND DISEASE 2018. doi:10.1038/s41419-018-0278-6. (IF 2018: 5.959) (WOS 2018 Q1) (IF 2023 8.100) (WOS 2023 Q1) (Cit.314)

41. Botticelli A, Onesti CE, Zizzari IG, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P. The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
ONCOTARGET 2017. doi: 10.18632/oncotarget.22242) (IF 2016: 5.168) (Cit.87)

42. Battisti F, Napoletano C, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Palchetti S, Bellati F, Benedetti Panici P, Torrisi MR, Caracciolo G, Altieri F, Nuti M, Rughetti A. Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells.
FRONTIERS IN IMMUNOLOGY 2017. doi: 10.3389/fimmu.2017.01179. (IF 2017 5.511) (WOS 2017 Q1) (IF 2023 5.700) (WOS 2023 Q1) (Cit.26)

43. Botticelli A*, Zizzari IG *, Mazzuca F, Ascierto PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. ONCOTARGET 2017. Doi: 0.18632/oncotarget.12985. (IF 2016: 5.168) (Cit.50)
*Equal contribution

44. Napoletano C, Bellati F, Ruscito I, Pernice M, Zizzari IG, Caponnetto S, Tomao F, Frigerio L, Liberati M, Rughetti A, Caserta D, Panici PB, Nuti M. Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. ANTICANCER RESEARCH 2016. doi; 10.21873/anticanres.11080. (IF 2016 1.937) (WOS 2016 Q3) (IF 2023 1.600) (WOS 2023 Q4) (Cit.11)

45. Iudicone P, Fioravanti D, Cicchetti E, Zizzari IG, Pandolfi A, Scocchera R, Fazzina R, Pierelli L. Interleukin-15 enhances cytokine induced killer (CIK)cytotoxic potential against epithelial cancer cell lines via an innate pathway.
HUMAN IMMUNOLOGY 2016. 10.1016/j.humimm.2016.09.003. (IF 2016 2.311) (WOS 2016 Q3 (IF 2023 3.100) (WOS 2023 Q3) (Cit.11)

46. Fazzina R, Iudicone P, Fioravanti D, Bonanno G, Totta P, Zizzari IG, Pierelli L. Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues. Stem Cell Research and Therapy 2016. Doi: 10.1186/s13287-016-0383-3. (IF 2016 4.211) (WOS 2016 Q2) (IF 2023 7.100) (WOS 2023 Q1) (Cit.31)

47. Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, Caponnetto S, Barchiesi G, Iadarola R, Pierelli L, Rughetti A, Bellati F, Panici PB, Nuti M. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology 2016. doi: 10.3892/ijo.2016.3386. (IF 2016 3.079) (WOS 2016 Q2) (IF 2023 4.500) (WOS 2023 Q1) (Cit.25)

48. Zizzari IG, Napoletano C, Battisti F, Rahimi H, Caponnetto S, Pierelli L, Nuti M, Rughetti A. MGL Receptor and Immunity: When the Ligand Can Make the Difference. Journal of Immunology Research 2015. doi: 10.1155/2015/450695. (IF 2015 2.812) (WOS 2015 Q3) (IF 2023 3.500) (WOS 2023 Q2) (Cit.59)

49. Zizzari IG, Martufi P, Battisti F, Rahimi H, Caponnetto S, Bellati F, Nuti M, Rughetti A, Napoletano C. The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions. PLoSONE 2015. doi: 10.1371/journal.pone.0132617. (IF 2015 3.057) (WOS 2015 Q1) (IF 2023 2.900) (WOS 2023 Q1) (Cit.21)

50. Rughetti A, Rahimi H, Belleudi F, Napoletano C, Battisti F, Zizzari IG, Antonilli M, Bellati F, Wandall HH, Benedetti Panici P, Burchell JM, Torrisi MR, Nuti M. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. Cancer Immunology Research 2014. doi: 10.1158/2326-6066.CIR-13-0112-T. (IF 2014 3.857) (WOS 2014 Q2) (IF 2023 8.100) (WOS 2023 Q1) (Cit.26)

51. Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Panici P, Nuti M. Past, present and future strategies of immunotherapy in gynecological malignancies. Current Molecular Medicine 2013. doi: 10.2174/1566524011313040014. (IF 2013 3.612) (WOS 2013 Q1) (IF 2023 2.200) (WOS 2023 Q3) (Cit.14)

52. Napoletano C*, Zizzari IG *, Rughetti A, Rahimi H, Irimura T, Clausen H, Wandall HH, Belleudi F, Bellati F, Pierelli L, Frati L, Nuti M. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. European Journal of Immunology. 2012. doi:10.1002/eji.201142086. (IF 2012 4.970) (WOS 2012 Q1) (IF 2023 4.500) (WOS 2023 Q2) (Cit.84)
*Equal contribution

53. Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M. Monoclonal antibodies in gynecological cancer: a critical point of view. Clinical & Developmental Immunology 2011. doi: 10.1155/2011/890758. (IF 2011 1.838) (WOS 2011 Q4) (IF 2015 3.603) (WOS 2015 Q2) (Cit.42)

54. Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, Rughetti A. HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. Journal of Molecular Medicine 2011. doi: 10.1007/s00109-011-0794-7. (IF 2011 4.668) (WOS 2011 Q1) (IF 2023 4.800) (WOS 2023 Q1) (Cit.13)

55. Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A. Immune effects of trastuzumab. Journal of Cancer. 2011. doi:10.7150/jca.2.317. (IF 2023 3.300) (WOS 2023 Q2) (Cit.33)

Editorials
56. Nuti M, Zizzari IG, Botticelli A, Putignani L, Marchetti P. The microbiota impact: bacteria shaping immunity, disease and response to therapy. Translational cancer research 2018. Doi: 10.21037/tcr.2018.05.25

57. Ruscito I, Braicu EI, Gasparri ML, Zizzari IG. Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. Biomed Research International 2018. doi: 10.1155/2018/6532019

Total Impact factor
(publication year) 309,56
Average Total Impact factor (publication year) 5,95
Total Impact factor
(JCR IF 2023) 300
Average Total impact factor
(JCR IF 2023) 5,65
Total H index 26
Normalized H index* 1,786
*H index divided by the academic seniority.

ORGANIZATION OF SCIENTIFIC MEETINGS

2024: Organization of Round Table “Percorsi immunoterapeutici in Oncologia: stato dell’arte e
Prospettive”, Sapienza University of Rome

2023-to date Organization of II level Master in “Immuno-Oncology and Cell therapies” Master (32680),
Sapienza University Rome

2016-2023 Organization of II level Master in “Immuno-Oncology” Master (29056), Sapienza University
Rome

2011: Organization Scientific Simposium BEMM 2011, edition II, Sapienza University Rome

CONTRIBUTES IN SCIENTIFIC MEETING AS INVITED SPEAKER

• 2nd International Congress of Immunology ECI 2009, Berlin, Germany. Talk: “HER2-based recombinant immunogen for dendritic cells targeting through FcγR”

• 5th ENII EFIS/EJI Immunology Summer School 2010, Capo Caccia, Italy. Talk “Mgl engagement modulates Dc phenotype and induces Erk1/2 and Nf-ΚB signaling pathways.”

• Educational Course: "Conferenza stampa con l’immunologo", Cattolica University, Rome July 2017. Talk “Esiste una relazione tra fattori clinici ed eventuali marker di risposta immunitaria?”

• Educational Course “Share the experience: Immunotherapy”-Rome, 2018. Talk: “Basic Immunology: cells and molecules”, Fondazione per la medicina personalizzata (Fmp)

• Course “Confronto aperto sulla migliore scelta terapeutica nel paziente con carcinoma polmonare stadio III” Umberto I Hospital, Rome. Talk: “L’importanza dell’aggiunta dell’immunoterapia”, 2019

• “Workshop Neoplasie Renali 3.0: Focus Classi Di Rischio”. Talk: “Le nuove frontiere nell’Immunologia e tumore del rene”. Novembre 2020 (online meeting)

• Preceptorship “Immunoterapia testa-collo e melanoma”. Talk “Meccanismi di resistenza all’immunoterapia”. Umberto I Hospital, Rome, September 2021

• “Yo-Yo: Young Oncologists In Immunoncology”. Talk “Immuno - Biomarkers: tessuto o solubile?”, Rome, November 2021 (online meeting, Fondazione per la medicina personalizzata (Fmp)

• Le Nuove Frontiere dei tumori testa-collo: le sfide del team multidisciplinare. Talk: “Immunomonitoring tra pazienti e laboratorio”, Rome, December 2021(online meeting)

• La Target Terapy nel trattamento del MelanomA - Talk:“Sistema immunitario e melanoma”, Rome 24 May 2022

• 41°Conferenza Nazionale di Citometri (GIC) – Talk:La profilazione immunologica nel percorso terapeutico del paziente oncologico”, Naples 17-19 May 2023

• 42°Conferenza Nazionale di Citometria (GIC) – Talk: La Citometria in Oncologia: dalla cellula al cross talk cellula-cellula”; Naples 5-7 June 2024

RESEARCH ACTIVITIES
• Study of the mechanisms of interaction between tumor and immune system: lectins, tumor microenvironment and immune cells
• Strategies of DC-targeting for an optimal anti-tumor immune response
• Monitoring the immune profiling of cancer patients in order to identify immune parameters as possible
predictors of response to immunotherapy and target therapies such as mechanisms of immune evasion
and resistance to immune checkpoints.
• Impact of cancer treatments on anti-tumor immune response
• Production of new immunogens for anti-cancer therapy

Keywords: Cancer Immunology, Immunotherapy, Cancer biology, Translational cancer research,